Search results
FDA Approves Biosimilars for Macular Degeneration Treatment
Healthline via AOL· 5 days agoThe FDA approved two interchangeable biosimilars to treat macular degeneration. The biosimilars work...
Effect of Low-Dose Aspirin on the Course of Age-Related Macular Degeneration
Journal of the American Medical Association· 4 days agoThis secondary analysis of the ASPREE randomized clinical trial, was conducted to evaluate the effect of long-term low-dose aspirin on age-related macular degeneration.
FDA grants approval for two Eylea biosimilars for eye conditions
Pharmaceutical Technology via Yahoo Finance· 6 days agoYesafili is a trademark of Biosimilars Newco, a Biocon Biologics...aim to mitigate retinal damage...
Daily Low-Dose Aspirin Fails to Prevent AMD in Older Adults
MedPage Today· 4 days agoUse of daily low-dose aspirin for 3 years didn't prevent age-related macular degeneration (AMD) in...
Biocon Biologics gets US FDA nod for biosimilar version of eye treatment drug Eylea
Investing.com· 6 days agoBiocon Biologics gets US FDA nod for biosimilar version of eye treatment drug Eylea
6 Everyday Habits That You Didn't Know Are Ruining Your Vision
CNET· 6 days agoIf you've never experienced any issues with your vision or your eye health for that matter, then you...
Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S....
WTRF Wheeling· 6 days agoBiocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the U.S. Food and Drug Administration ...
FDA approves 2 Eylea biosimilars
Becker’s Hospital Review· 7 days agoThe FDA granted approval to Biocon Biologics' drug Yesafili and Samsung Bioepis and Biogen's drug Opuviz, the agency announced May 20. The two drugs are biosimilars for Eylea, an injection made ...
1 Stock That More Than Doubled This Year That I Wouldn't Touch With a 10-Foot Pole
Motley Fool via Yahoo Finance· 3 days agoSo by any standard, if these projections work out, Ocugen is severely undervalued. And that's...
2 Biotech Stocks to Buy in May
Motley Fool via Yahoo Finance· 2 days agoFor reference, Dupixent's sales were $11.59 billion last year. Regeneron's second-most-important product, Eylea, is at a critical point. Eylea is a...